Live Breaking News & Updates on Cumulative Toxicity

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine. ....

Sara Hurvitz , Breast Cancer , Her2 Breast Cancer , Her2 Positive Breast Cancer , Metastatic Breast Cancer , Third Line Therapy , Brain Metastases , Cns Metastases , Cumulative Toxicity , Cardiac Toxicity , Tyrosine Kinase Inhibitors , Topoisomerase Inhibitors , Antibody Drug Conjugates , Trastuzumab Deruxtecan , Trastuzumab Emtansine , T Dm1 , T Dxd , Cns Progression ,